Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Salarius Pharmaceuticals Inc (SLRX)

Salarius Pharmaceuticals Inc (SLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard GlobeNewswire - Mon Jul 14, 7:30AM CDT

HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock...

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies GlobeNewswire - Wed Jul 9, 7:30AM CDT

SLRX : 0.6780 (-9.36%)
Salarius: Q1 Earnings Snapshot AP - Wed May 14, 4:33PM CDT

Salarius: Q1 Earnings Snapshot

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board GlobeNewswire - Wed Apr 16, 7:00AM CDT

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses GlobeNewswire - Wed Mar 26, 7:00AM CDT

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update GlobeNewswire - Mon Mar 24, 7:00AM CDT

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers GlobeNewswire - Mon Feb 3, 7:00AM CST

SLRX : 0.6780 (-9.36%)
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement GlobeNewswire - Mon Jan 13, 7:00AM CST

SLRX : 0.6780 (-9.36%)
Salarius: Q3 Earnings Snapshot AP - Thu Nov 14, 2024

Salarius: Q3 Earnings Snapshot

SLRX : 0.6780 (-9.36%)
Salarius: Q2 Earnings Snapshot AP - Fri Aug 9, 2024

Salarius: Q2 Earnings Snapshot

SLRX : 0.6780 (-9.36%)

Barchart Exclusives

Growth vs. Value Is The Wrong Question: Here’s What Actually Makes Money Barchart - 1 hour ago
Forget the style boxes; this market rewards those who spot structure, behavior, and catalysts before the crowd. Here's how real money is made now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot